PTPRC and neoplasm: We observed that mice treated with MRF/magnet application demonstrated increased tumor necrotic (tubulin+7AAD−) cell death of CD45(−) cells (non-tumor cells or hematopoietic cells) (Fig. 2D–F) compared to MRF alone (Fig. 2D–E; 35% versus 50% respectively).